Status:
NOT_YET_RECRUITING
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions:
NSCLC
BRAF V600E Mutation
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
Detailed Description
lung cancer is the leading cause of morbidity and mortality in China, and non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The incidence of V-Raf murine sarcoma viral onc...
Eligibility Criteria
Inclusion
- Inoperable stage IIIB-IV patients with non-small cell lung cancer;
- BRAF V600E mutation;
- Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;
- ECOG PS 0/1;
- The diameter of the primary lesion should be at least 1cm;
- Previous or current aspirin treatment was allowed
Exclusion
- The patient is currently receiving other anticoagulant therapy;
- The patient was previously treated with systemic anti-NSCLC;
- The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.
- The patient had contraindications for dalafenib or trametinib and aspirin use;
- Patients who refused follow-up visits;
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05988697
Start Date
November 1 2023
End Date
April 1 2027
Last Update
October 12 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.